LY-CoV1404 (bebtelovimab) potently neutralizes SARS-CoV-2 variants. Kathryn Westendorf , Stefanie Žentelis , Lingshu Wang , Denisa Foster , Peter Vaillancourt , Matthew Wiggin , Erica Lovett , Robin van der Lee , Jörg Hendle , Anna Pustilnik , J Michael Sauder , Lucas Kraft , Yuri Hwang , Robert W Siegel , Jinbiao Chen , Beverly A Heinz , Richard E Higgs , Nicole L Kallewaard , Kevin Jepson , Rodrigo Goya , Maia A Smith , David W Collins , Davide Pellacani , Ping Xiang , Valentine de Puyraimond , Marketa Ricicova , Lindsay Devorkin , Caitlin Pritchard , Aoise O'Neill , Kush Dalal , Pankaj Panwar , Harveer Dhupar , Fabian A Garces , Courtney A Cohen , John M Dye , Kathleen E Huie , Catherine V Badger , Darwyn Kobasa , Jonathan Audet , Joshua J Freitas , Saleema Hassanali , Ina Hughes , Luis Munoz , Holly C Palma , Bharathi Ramamurthy , Robert W Cross , Thomas W Geisbert , Vineet Menacherry , Kumari Lokugamage , Viktoriya Borisevich , Iliana Lanz , Lisa Anderson , Payal Sipahimalani , Kizzmekia S Corbett , Eun Sung Yang , Yi Zhang , Wei Shi , Tongqing Zhou , Misook Choe , John Misasi , Peter D Kwong , Nancy J Sullivan , Barney S Graham , Tara L Fernandez , Carl L Hansen , Ester Falconer , John R Mascola , Bryan E Jones , Bryan C Barnhart bioRxiv : the preprint server for biology（2022）
摘要
LY-CoV1404 potently neutralizes SARS-CoV-2 authentic virus and known variants of concern including the B.1.1.529 (Omicron), the BA.2 Omicron subvariant, and B.1.617.2 (Delta) variantsNo loss of potency against currently circulating variantsBinding epitope on RBD of SARS-CoV-2 is rarely mutated in GISAID databaseBreadth of neutralizing activity and potency supports clinical development.
更多 查看译文
关键词
bebtelovimab, ly-cov, sars-cov
AI 理解论文
溯源树
样例
